● Recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Condition: Melanoma · Sponsor: The Netherlands Cancer Institute

PhasePhase 1/Phase 2

Planned participants96

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

This description comes directly from the study's public registry record.

Talk to the study team

Christian Blank, Prof · +31205129111 · c.blank@nki.nl

Always discuss trial participation with your own doctor first.

Locations (6)

Amsterdam University Medical Center	Amsterdam, Netherlands	Not Yet Recruiting
Antoni van Leeuwenhoek Hospital	Amsterdam, Netherlands	Recruiting
University Medical Center Groningen	Groningen, Netherlands	Recruiting
Leiden University Medical Center	Leiden, Netherlands	Not Yet Recruiting
Erasmus University Medical Center	Rotterdam, Netherlands	Not Yet Recruiting
University Medical Center Utrecht	Utrecht, Netherlands	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06240143